{"id":411618,"date":"2021-01-11T06:05:09","date_gmt":"2021-01-11T11:05:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411618"},"modified":"2021-01-11T06:05:09","modified_gmt":"2021-01-11T11:05:09","slug":"idera-pharmaceuticals-to-present-at-upcoming-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/","title":{"rendered":"Idera Pharmaceuticals to Present at Upcoming Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>EXTON, Pa., Jan.  11, 2021  (GLOBE NEWSWIRE) &#8212; Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.<\/p>\n<p>\u201c2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available from our ILLUMINATE program will show that tilsotolimod, the most advanced TLR9 agonist therapy in development, can offer meaningful alternatives to patients suffering from advanced anti-PD-1 refractory melanoma and, potentially, colorectal cancer,\u201d stated Vincent Milano, Idera\u2019s Chief Executive Officer. \u201cWe\u2019re looking forward to sharing topline response data from ILLUMINATE-301 late in this quarter and a data update from ILLUMINATE-206 in the third quarter of the year.\u201d<\/p>\n<p>Continued Mr. Milano, \u201cOur entire team is driven by our goal of making a difference for patients and is unified in its persistence to help ensure the quality of our clinical results, NDA and commercial readiness, and a strong financial outlook that includes existing cash that is expected to take us into the first quarter of 2022. We have confidence that this is the year Idera will deliver on its long history of innovative science and begin to turn that history into a business reality.\u201d<\/p>\n<p>The Company plans to share further corporate and ILLUMINATE program updates at the following conferences in January:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>39<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual J.P. Morgan Healthcare Conference, January 11-14, 2021<\/strong><br \/>\n          <br \/>Presentation on January 13, 2021, 3:40 pm EST<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>H.C. Wainwright BioConnect 2021 Conference, January 11-14, 2021<\/strong><br \/>\n          <br \/>Pre-recorded conversation available January 11, 2021, 6:00 am EST<\/li>\n<\/ul>\n<p>Live and archived webcasts of the investor conference presentations will be available in the Investor Relations section of the Idera website.<\/p>\n<p>\n        <strong><br \/>\n          <em>About Idera Pharmaceuticals<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Harnessing the approach of the earliest researchers in immunotherapy and the company\u2019s vast experience in developing proprietary immunology platforms, Idera\u2019s development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs. To learn more about Idera, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=njXfFIwKYyfl38BYNrCvurVB9U3H2ygg9LYnnGklmVMpowBysX9Doe9PJDwllBPeUhSVFZNfCfoImVWjfkVVk7ltuE5VwHW4c0CciZdUMWE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.iderapharma.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Forward Looking Statements<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company&#8217;s strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, clinical trials, plans, and objectives of management, are forward-looking statements. The words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; &#8220;projects,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; and &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company&#8217;s forward-looking statements. There are a number of important factors that could cause Idera&#8217;s actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether the Company\u2019s cash resources will be sufficient to fund the Company\u2019s continuing operations and the further development of the Company\u2019s programs for the period anticipated; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of the results that will be generated in future clinical trials, including in clinical trials in different disease indications; whether products based on Idera&#8217;s technology will advance into or through the clinical trial process when anticipated or at all or warrant submission for regulatory approval; whether such products will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company&#8217;s products receive approval, they will be successfully distributed and marketed; whether the Company&#8217;s collaborations will be successful; and such other important factors as are set forth under the caption &#8220;Risk factors&#8221; in the Company\u2019s Annual Report filed on Form 10-K for the period ended December 31, 2019 and the Company\u2019s Quarterly Report filed on Form 10-Q for the period ended September 30, 2020. Although Idera may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"4\" style=\"text-align: center;vertical-align: middle\"> Idera Pharmaceuticals Contacts: <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%\">\u00a0<\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%\">\u00a0<\/td>\n<td style=\"max-width:49%;width:49%;min-width:49%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td> Jill Conwell <\/td>\n<td>\u00a0<\/td>\n<td> John J. Kirby <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td> Investor Relations &amp; <\/td>\n<td>\u00a0<\/td>\n<td> Chief Financial Officer <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td> Corporate Communications <\/td>\n<td>\u00a0<\/td>\n<td> Phone (484) 348-1627 <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td> Phone (484) 348-1675 <\/td>\n<td>\u00a0<\/td>\n<td> JKirby@IderaPharma.com <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td> JConwell@IderaPharma.com <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3330b10c-28d3-45a8-99af-a54430c1bbbd\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. \u201c2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available from our ILLUMINATE program will show that tilsotolimod, the most advanced TLR9 agonist therapy in development, can offer meaningful alternatives to patients suffering from advanced anti-PD-1 refractory melanoma and, potentially, colorectal cancer,\u201d stated Vincent Milano, Idera\u2019s Chief Executive Officer. \u201cWe\u2019re looking forward to sharing topline response data from ILLUMINATE-301 late in this quarter and a data update from ILLUMINATE-206 in the third quarter of the year.\u201d Continued Mr. Milano, \u201cOur entire team is driven &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Idera Pharmaceuticals to Present at Upcoming Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411618","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Idera Pharmaceuticals to Present at Upcoming Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Idera Pharmaceuticals to Present at Upcoming Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. \u201c2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available from our ILLUMINATE program will show that tilsotolimod, the most advanced TLR9 agonist therapy in development, can offer meaningful alternatives to patients suffering from advanced anti-PD-1 refractory melanoma and, potentially, colorectal cancer,\u201d stated Vincent Milano, Idera\u2019s Chief Executive Officer. \u201cWe\u2019re looking forward to sharing topline response data from ILLUMINATE-301 late in this quarter and a data update from ILLUMINATE-206 in the third quarter of the year.\u201d Continued Mr. Milano, \u201cOur entire team is driven &hellip; Continue reading &quot;Idera Pharmaceuticals to Present at Upcoming Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T11:05:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Idera Pharmaceuticals to Present at Upcoming Conferences\",\"datePublished\":\"2021-01-11T11:05:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/\"},\"wordCount\":801,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/\",\"name\":\"Idera Pharmaceuticals to Present at Upcoming Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=\",\"datePublished\":\"2021-01-11T11:05:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/idera-pharmaceuticals-to-present-at-upcoming-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Idera Pharmaceuticals to Present at Upcoming Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Idera Pharmaceuticals to Present at Upcoming Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Idera Pharmaceuticals to Present at Upcoming Conferences - Market Newsdesk","og_description":"EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. \u201c2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available from our ILLUMINATE program will show that tilsotolimod, the most advanced TLR9 agonist therapy in development, can offer meaningful alternatives to patients suffering from advanced anti-PD-1 refractory melanoma and, potentially, colorectal cancer,\u201d stated Vincent Milano, Idera\u2019s Chief Executive Officer. \u201cWe\u2019re looking forward to sharing topline response data from ILLUMINATE-301 late in this quarter and a data update from ILLUMINATE-206 in the third quarter of the year.\u201d Continued Mr. Milano, \u201cOur entire team is driven &hellip; Continue reading \"Idera Pharmaceuticals to Present at Upcoming Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T11:05:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Idera Pharmaceuticals to Present at Upcoming Conferences","datePublished":"2021-01-11T11:05:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/"},"wordCount":801,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/","name":"Idera Pharmaceuticals to Present at Upcoming Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=","datePublished":"2021-01-11T11:05:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzIxMiMzOTExNzA1IzIwMDc1Mzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/idera-pharmaceuticals-to-present-at-upcoming-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Idera Pharmaceuticals to Present at Upcoming Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411618"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411618\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}